{
    "root": "2f9d08d0-1f6c-0bf3-e063-6394a90a2b6f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cyclophosphamide",
    "value": "20250305",
    "ingredients": [
        {
            "name": "CYCLOPHOSPHAMIDE",
            "code": "8N3DW7272P"
        }
    ],
    "indications": "cyclophosphamide alkylating indicated treatment : malignant diseases : malignant lymphomas : hodgkin 's disease , lymphocytic lymphoma , mixed-cell type lymphoma , histiocytic lymphoma , burkitt 's lymphoma ; multiple myeloma , leukemias , mycosis fungoides , neuroblastoma , adenocarcinoma ovary , retinoblastoma , breast carcinoma ( 1.1 ) minimal change nephrotic syndrome pediatric patients : biopsy proven minimal change nephrotic syndrome patients failed adequately respond unable tolerate adrenocorticosteroid therapy ( 1.2 ) limitations : safety effectiveness treatment nephrotic syndrome adults renal disease established .",
    "contraindications": "immediately , adequate amounts fluid ingested infused force diuresis order reduce risk urinary tract toxicity . therefore , cyclophosphamide administered morning .",
    "warningsAndPrecautions": "cyclophosphamide injection , usp sterile white powder containing cyclophosphamide supplied vials single dose . cyclophosphamide injection , usp ndc 0781-3233-94 500 mg vial , carton 1 ndc 0781-3244-94 1 g vial , carton 1 ndc 0781-3255-94 2 g vial , carton 1 store vials 25°c ( 77°f ) . transport storage cyclophosphamide vials , temperature influences lead melting active ingredient , cyclophosphamide . [ ( 2.3 ) ] . cyclophosphamide antineoplastic product . follow special handling disposal procedures . 1",
    "adverseReactions": "hypersensitivity cyclophosphamide contraindicated patients history severe hypersensitivity , metabolites , components product . anaphylactic including death reported cyclophosphamide . possible cross-sensitivity alkylating agents occur . urinary outflow obstruction cyclophosphamide contraindicated patients urinary outflow obstruction [ ( 5.2 ) ] .",
    "indications_original": "Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established.",
    "contraindications_original": "During or immediately after the administration, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, cyclophosphamide should be administered in the morning.",
    "warningsAndPrecautions_original": "Cyclophosphamide for Injection, USP is a sterile white powder containing cyclophosphamide and is supplied in vials for single dose use.\n                  Cyclophosphamide for Injection, USP\n                  NDC 0781-3233-94        500 mg vial, carton of 1\n                  NDC 0781-3244-94        1 g vial, carton of 1\n                  NDC 0781-3255-94        2 g vial, carton of 1\n                  Store vials at or below 25°C (77°F). During transport or storage of cyclophosphamide vials, temperature influences can lead to melting of the active ingredient, cyclophosphamide. \n       \n \n  [see Dosage and Administration (\n        \n  \n   2.3)]\n       \n \n  .\n      \n\n \n                   Cyclophosphamide is an antineoplastic product. Follow special handling and disposal procedures.\n       \n \n  1",
    "adverseReactions_original": "Hypersensitivity \n        \n  \n   Cyclophosphamide is contraindicated in patients who have a history of severe hypersensitivity reactions to it, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Possible cross-sensitivity with other alkylating agents can occur.\n                     \n                     Urinary Outflow Obstruction\n        \n  \n   Cyclophosphamide is contraindicated in patients with urinary outflow obstruction \n        \n  \n   [see Warnings and Precautions (\n         \n   \n    5.2)]."
}